71 related articles for article (PubMed ID: 232917)
1. Renal bone disorders in children: therapy with vitamin D3 or 1,25-dihydroxycholecalciferol.
Bulla M; Delling G; Offermann G; Ziegler R; Benz G; Lühmann H; Sanchez de Reutter A; Severin M
Proc Eur Dial Transplant Assoc; 1979; 16():644-8. PubMed ID: 232917
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
[TBL] [Abstract][Full Text] [Related]
4. [Parathormone and vitamin d3-metabolites in healthy children and children with chronic renal failure before and after kidney transplantation].
Pistor K; Reinhardt D; Grosse-Hohmann E; Keck E
Monatsschr Kinderheilkd; 1982 Sep; 130(9):714-20. PubMed ID: 6755227
[TBL] [Abstract][Full Text] [Related]
5. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
6. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results.
Coen G; Mazzaferro S; Bonucci E; Ballanti P; Massimetti C; Donato G; Landi A; Smacchi A; Della Rocca C; Cinotti GA
Miner Electrolyte Metab; 1986; 12(5-6):375-82. PubMed ID: 3492662
[TBL] [Abstract][Full Text] [Related]
7. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
8. Hyperparathyroid bone disease in diabetic renal failure.
Cundy TF; Humphreys S; Watkins PJ; Parsons V
Diabetes Res; 1990 Aug; 14(4):191-6. PubMed ID: 2132193
[TBL] [Abstract][Full Text] [Related]
9. [Comparative studies of calcium resorption modified by vitamin D2 and D3 in patients with chronic renal failure and dialysis patients].
Fünfstück R; Günther K; Tietz U; Brandstädt A; Stein G; Hartwich R
Z Urol Nephrol; 1986 Apr; 79(5):287-94. PubMed ID: 3017021
[TBL] [Abstract][Full Text] [Related]
10. Long-term administration of vitamin D steroles in incipient and advanced renal failure: effect on bone histology.
Malluche HH; Ritz E; Werner E; Meyer-Sabellek WA
Clin Nephrol; 1978 Dec; 10(6):219-28. PubMed ID: 215365
[TBL] [Abstract][Full Text] [Related]
11. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F
Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788
[TBL] [Abstract][Full Text] [Related]
12. [Corneal deposits in children on dialysis and treatment with vitamin D3 and 1,25 DHCC (author's transl)].
Severin M; Bulla M
Klin Monbl Augenheilkd; 1979 Nov; 175(5):670-6. PubMed ID: 232733
[TBL] [Abstract][Full Text] [Related]
13. [Serum osteocalcin in children with chronic renal insufficiency].
Peco-Antić A; Nastić-Mirić D; Milikić V; Babić D; Pejcić I; Kostić M; Paripović V; Jovanović O; Kruscić D; Mancić J
Srp Arh Celok Lek; 1996; 124(9-10):227-31. PubMed ID: 9102853
[TBL] [Abstract][Full Text] [Related]
14. Percent true calcium absorption, mineral metabolism, and bone mass in children with arthritis: effect of supplementation with vitamin D3 and calcium.
Hillman LS; Cassidy JT; Chanetsa F; Hewett JE; Higgins BJ; Robertson JD
Arthritis Rheum; 2008 Oct; 58(10):3255-63. PubMed ID: 18821668
[TBL] [Abstract][Full Text] [Related]
15. [Effect of bile on intestinal calcium and vitamin D absorption. Animal experiment studies in swine].
Braun F
Wien Klin Wochenschr Suppl; 1986; 166():1-23. PubMed ID: 3008448
[TBL] [Abstract][Full Text] [Related]
16. [Studies on intestinal 47 Calcium absorption in healthy subjects and patients with chronic renal failure as well as on the significance of vitamin D 3 or 25-hydroxycholecalciferol therapy in renal osteopathy].
Hesch RD; Gerlach W; Henning HV; Emrich D; Scheler F; Kattermann R
Dtsch Med Wochenschr; 1972 Nov; 97(45):1735-8 passim. PubMed ID: 4343379
[No Abstract] [Full Text] [Related]
17. [Influence of vitamin D therapy on renal osteodystrophy in children (author's transl)].
Bulla M; Stock GJ; Delling G; Hofmann H; Offermann G
Klin Wochenschr; 1980 Mar; 58(5):237-47. PubMed ID: 6249957
[TBL] [Abstract][Full Text] [Related]
18. Model for skeletal resistance to vitamin D in renal failure.
Weisbrode SE; Capen CC
Fed Proc; 1976 Apr; 35(5):1225-31. PubMed ID: 177317
[TBL] [Abstract][Full Text] [Related]
19. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis.
Berl T; Berns AS; Huffer WE; Alfrey AC; Arnaud CD; Schrier RR
Contrib Nephrol; 1980; 18():72-81. PubMed ID: 6243528
[TBL] [Abstract][Full Text] [Related]
20. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I
Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
